Biomarkers are essential in the early detection, diagnosis, prognosis, and monitoring of neurodegenerative diseases. In Alzheimer’s disease, established biomarkers include cerebrospinal fluid (CSF) levels of amyloid-beta (Aβ42), total tau, and phosphorylated tau (p-tau), which reflect underlying pathology and can be measured years before clinical symptoms arise. Blood-based biomarkers, such as plasma p-tau181 and neurofilament light chain (NfL), are gaining momentum due to their accessibility and diagnostic potential. In diseases like Parkinson’s, Huntington’s, and ALS, efforts are underway to identify fluid, imaging, and genetic biomarkers that correlate with disease onset and progression. Neuroimaging techniques (e.g., amyloid PET, tau PET, volumetric MRI) also serve as valuable biomarkers in research and clinical settings.

Biomarkers are increasingly used to stratify patients in clinical trials and assess therapeutic response. Multi-omics approaches combining proteomics, metabolomics, and transcriptomics are expanding the biomarker landscape. The Journal of Alzheimer’s & Neurodegenerative Diseases invites research focused on the discovery, validation, and clinical application of biomarkers that enhance our understanding of disease mechanisms and support the development of personalized medicine strategies in neurodegenerative care.